NCT01845181View on ClinicalTrials.gov

"First-in-human Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers"

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2013

Conditions
Asthma
Interventions
DRUG

PBF-680

Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).

DRUG

Placebo

1 or 2 or 3 capsules of placebo.

Trial Locations (2)

08302

Palobiofarma S.L. (molecule owner), Mataró

08025

CIM-Sant Pau. Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Collaborators (1)

Palo Biofarma, S.L
All Listed Sponsors
collaborator

Palo Biofarma, S.L

INDUSTRY

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER